Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04045795
Other study ID # TCD15484
Secondary ID U1111-1211-95252
Status Completed
Phase Phase 1
First received
Last updated
Start date August 6, 2019
Est. completion date March 27, 2024

Study information

Verified date April 2024
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objectives: - To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) - To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device - To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: - To estimate absolute bioavailability of SC and IV isatuximab - To measure receptor occupancy (RO) after isatuximab SC versus IV administration - To assess efficacy of isatuximab after SC and IV administration - To assess patient expectations prior to and patient experience and satisfaction after SC administration - To evaluate potential immunogenicity of SC or IV isatuximab


Description:

Total study duration is variable depending on treatment and follow-up periods, including 21 days of screening, and treatment period until disease progression, unacceptable adverse reaction or other reason for discontinuation. End of treatment will be 30 days after last administration of investigational medicinal product, or before further anti-myeloma therapy, whichever comes first; approximately 14 months after first study treatment administration.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date March 27, 2024
Est. primary completion date March 27, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. - Participant must be above 18 years of age or country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent. - Participant has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has relapsed following a response, according to International Myeloma Working Group (IMWG) criteria. - Participant has received at least two previous therapies including lenalidomide and a proteasome inhibitor and has demonstrated disease progression on last therapy or after completion of the last therapy. - Participants with measurable disease defined as at least one of the following: - Serum M protein = 0.5 g/dL (=5 g/L). - Urine M protein = 200 mg/24 hours. - Serum free light chain (FLC) assay: Involved FLC assay = 10 mg/dL (= 100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65). - Male or female: Contraceptive use by men or women Exclusion criteria: - Malignancy within 3 years prior to enrollment. - Eastern Cooperative Oncology Group (ECOG) performance status score >2. - Inadequate hematological, liver or renal function. - Serum calcium (corrected for albumin) level above the upper limit of normal (ULN) range. - Patients with prior anti-CD38 treatment are excluded if: - Refractory to anti-CD38 treatment defined as progression on or within 60 days of the last dose of the anti-CD38 or, - Intolerant to the anti-CD38 previously received or, - Progression after initial response on anti-CD38 therapy with a washout period inferior to 9 months before the first dose of isatuximab SC or IV. - Participant did not achieve a minimal response or better to at least one of the previous lines of treatment (ie, primary refractory disease is not eligible). - Received any investigational drug within 14 days or 5 half-lives of the investigational drug, whichever is longer. - Prior anti-cancer therapy within 14 days. - Any >Grade 1 adverse reaction unresolved from previous treatments according to the NCI-CTCAE v5.0. The presence of alopecia or peripheral neuropathy = Grade 2 without pain is allowed. - Previous allogeneic stem cell transplantation with active Graft Versus Host Disease or being under immunosuppressive therapy in the last 2 months previously to the inclusion in the trial. - Daily requirement for corticosteroids. - Known to be HIV+ or to have hepatitis A or uncontrolled or active hepatitis B virus (HBV) infection (patients with positive HBsAg [HBsAg] and/or HBV DNA) or active HCV (HCV) infection (positive HCV RNA and negative anti-HCV). - Active tuberculosis and severe infections requiring treatment with antibiotic parenteral administration. - Any clinically significant, uncontrolled medical conditions that, in the Investigator's opinion, would expose excessive risk to the patient or may interfere with compliance or interpretation of the study results. - History of erythema multiforme or severe hypersensitivity to prior immunomodulatory drugs (IMiDs). - Hypersensitivity or history of intolerance to immunomodulatory drugs (IMiDs), dexamethasone, mannitol, pregelatinized starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine hydrochloride, poloxamer 188, sucrose or any of the other components of study therapy that are not amenable to premedication with steroids and histamine H2 blockers or would prohibit further treatment with these agents. - Inability to tolerate thromboprophylaxis. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
isatuximab SAR650984 IV
Pharmaceutical form: solution Route of administration: intravenous
pomalidomide
Pharmaceutical form: tablet Route of administration: oral
dexamethasone
Pharmaceutical form: tablet Route of administration: oral
isatuximab SAR650984 SC
Pharmaceutical form: solution Route of administration: subcutaneous
Device:
Investigational injector device
Subcutaneous administration

Locations

Country Name City State
Australia Investigational Site Number : 0360002 Blacktown New South Wales
Australia Investigational Site Number : 0360004 Fitzroy Victoria
Australia Investigational Site Number : 0360003 Richmond Victoria
Australia Investigational Site Number : 0360001 Wollongong New South Wales
Belgium Investigational Site Number : 0560001 Leuven
France Investigational Site Number : 2500001 Nantes
France Investigational Site Number : 2500002 TOULOUSE Cedex 9
Japan Investigational Site Number : 3920002 Okayama-shi Okayama
Japan Investigational Site Number : 3920001 Shibuya-ku Tokyo
Spain Investigational Site Number : 7240001 Badalona Catalunya [Cataluña]
Spain Investigational Site Number : 7240002 Santander Cantabria
United States Gabrail Cancer Center Site Number : 8400001 Canton Ohio
United States City of Hope Site Number : 8400002 Duarte California
United States ~Banner MD Anderson Cancer Center Site Number : 8400005 Gilbert Arizona

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  France,  Japan,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of adverse events (AEs) Number of participants with adverse events Baseline to 30 days after last study treatment administration (up to approximately 14 months after first study treatment administration)
Primary Pharmacokinetic (PK) assessment: Ceoi Concentration observed at the end of infusion (Ceoi) Baseline to end of treatment (EOT) after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: Cmax Maximum concentration observed after the first infusion (Cmax) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: tmax Time to reach Cmax (tmax) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: Clast Last concentration observed above the lower limit of quantification after the first infusion (Clast) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: tlast Time of Clast (tlast) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: Ctrough Concentration observed just before treatment administration during repeated dosing (Ctrough) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: AUClast Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to time of the last concentration observed above the lower limit of quantification (ie, Clast) (AUClast) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Primary PK assessment: AUC0 T Area under the plasma concentration versus time curve calculated over the dosing interval T (168h or 336h) (AUC0 T) Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Secondary Estimation of absolute bioavailability of isatuximab Absolute bioavailability of isatuximab SC, expressed as a percentage, estimated from AUC0-168h obtained after intravenous (IV) and extravascular (EV) administration Day 8
Secondary Overall response rate (ORR) ORR is the proportion of patients with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) using the IMWG response criteria From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Duration of response (DOR) Time from the date of the first response to the date of first progressive disease (PD) or death, whichever happens first From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Time to response (TTR) Time from the date of first study treatment to the first response From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Time to progression (TTP) Time from date of first study treatment to date of first documentation of progressive disease From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Overall survival (OS) Time from the date of first study treatment to date of death from any cause From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Clinical benefit rate (CBR) Proportion of patients with sCR, CR, VGPR, PR or minimal response (MR) according to IMWG criteria From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Progression free survival (PFS) Time from date of first study treatment to date of first documentation of progressive disease or death From day -21 to day 60 after last study treatment (up to approximately 14 months after first study treatment administration)
Secondary Comparison of patient expectations and satisfaction: Patient Expectations and Satisfaction Questionnaires Comparison of patient expectations and satisfaction will be assessed using Patient Expectations and Satisfaction Questionnaires before and after subcutaneous (SC) administration, where a score of 1 = not satisfied and a score of 5 = extremely satisfied Cycles 1 and 2 (28 days per Cycle), and 30 days after last isatuximab administration (up to approximately 14 months after first study treatment administration)
Secondary Immunogenicity: Anti drug antibody levels Incidence of patients with anti drug antibodies against isatuximab Baseline to EOT after isatuximab SC and to Cycle 10 after IV (28 days per Cycle)
Secondary Biomarker: Change in CD38 receptor occupancy Change in CD38 receptor occupancy from baseline At screening and at Day 1 of Cycle 2 (28 days per Cycle) (predose); to be stopped once the isatuximab SC dose has been selected.
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1